Condition
Squamous Cell Carcinoma of Lung
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Unknown2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05943795Phase 3Active Not Recruiting
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
NCT02009605Phase 2UnknownPrimary
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer
NCT01969955Phase 2UnknownPrimary
Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer
Showing all 3 trials